GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Float Percentage Of Total Shares Outstanding

Boundless Bio (Boundless Bio) Float Percentage Of Total Shares Outstanding : 77.10% (As of May. 03, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Boundless Bio's float shares is 17.15 Mil. Boundless Bio's total shares outstanding is 22.24 Mil. Boundless Bio's float percentage of total shares outstanding is 77.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Boundless Bio's Insider Ownership is 1.73%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Boundless Bio's Institutional Ownership is 0.00%.


Boundless Bio Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Boundless Bio's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=17.15/22.24
=77.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boundless Bio (Boundless Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
Traded in Other Exchanges
N/A
Address
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Boundless Bio (Boundless Bio) Headlines

From GuruFocus